CLIA Kit for Alpha-1-Microglobulin (a1M) Homo sapiens (Human) Sandwich CLIA

AMBP; UTI; HCP; EDC1; HI30; IATIL; ITILC; ITI; ITIL; Alpha 1 Microglobulin/Bikunin Precursor; Growth-inhibiting protein 19; Uristatin; Uronic-Acid-Rich Protein; Trypstatin

Add to Cart Distributors
Share your citation Upload your experimental result Review Leave a message

Share a new citation as an author

Upload your experimental result


Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

E-mail address*
Verification code* CheckCode
  • CLIA Kit for Alpha-1-Microglobulin (a1M) Packages (Simulation)
  • CLIA Kit for Alpha-1-Microglobulin (a1M) Packages (Simulation)
  • CLIA Kit for Alpha-1-Microglobulin (a1M) Results demonstration
  • SCA217Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered


Matrices listed below were spiked with certain level of recombinant Alpha-1-Microglobulin (a1M) and the recovery rates were calculated by comparing the measured value to the expected amount of Alpha-1-Microglobulin (a1M) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 92-105 99
EDTA plasma(n=5) 92-105 102
heparin plasma(n=5) 82-103 88


Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Alpha-1-Microglobulin (a1M) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Alpha-1-Microglobulin (a1M) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%


The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Alpha-1-Microglobulin (a1M) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 95-104% 78-104% 89-96% 87-97%
EDTA plasma(n=5) 98-105% 78-103% 98-105% 95-102%
heparin plasma(n=5) 93-101% 79-99% 92-104% 84-98%


The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Alpha-1-Microglobulin (a1M)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Alpha-1-Microglobulin (a1M). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Alpha-1-Microglobulin (a1M). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Alpha-1-Microglobulin (a1M) level in the sample or standard.;


  • Proteomic Identification of Human Urinary Biomarkers in Diabetes Mellitus Type 2 Liebert: 20100078
  • Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2PubMed: 21130593
  • Proteomic Profiling for Peritoneal Dialysate: Differential Protein Expression in Diabetes MellitusPubMed: PMC3679811
  • Identifizierung neuer potentieller Biomarker für das Kolonkarzinom sowie dessen VorstufenInfo:Source
  • Activated Α7nachr Improves Postoperative Cognitive Dysfunction and Intestinal Injury Induced by Cardiopulmonary Bypass in Rats: Inhibition of the Proinflammatory …Pubmed:29672286
  • Urinary Proteomics for the Early Diagnosis of Diabetic Nephropathy in Taiwanese PatientsPubmed: 30486327

Recommend products